Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free NFX Stock Alerts

Nuformix (NFX) Competitors

Nuformix logo
GBX 0.20 +0.01 (+4.21%)
As of 12:21 PM Eastern
Compare

NFX vs. FAB, RLM, NSCI, GENF, and CIZ

Should you buy Nuformix stock or one of its competitors? MarketBeat compares Nuformix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuformix include Fusion Antibodies (FAB), Realm Therapeutics (RLM), NetScientific (NSCI), Genflow Biosciences (GENF), and Cizzle Biotechnology (CIZ). These companies are all part of the "biotechnology" industry.

How does Nuformix compare to Fusion Antibodies?

Fusion Antibodies (LON:FAB) and Nuformix (LON:NFX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Nuformix has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Nuformix's return on equity of -83.53% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-91.92% -210.32% -63.78%
Nuformix N/A -83.53%-17.20%

In the previous week, Fusion Antibodies' average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.

Company Overall Sentiment
Fusion Antibodies Neutral
Nuformix Neutral

Nuformix has lower revenue, but higher earnings than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than Nuformix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£1.60M8.70-£4.10M-£1.50N/A
NuformixN/AN/A-£383.40K-£0.03N/A

Fusion Antibodies has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Nuformix has a beta of 1.537, indicating that its stock price is 54% more volatile than the broader market.

7.6% of Fusion Antibodies shares are held by institutional investors. Comparatively, 0.1% of Nuformix shares are held by institutional investors. 5.9% of Fusion Antibodies shares are held by insiders. Comparatively, 7.5% of Nuformix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Nuformix beats Fusion Antibodies on 8 of the 10 factors compared between the two stocks.

How does Nuformix compare to Realm Therapeutics?

Realm Therapeutics (LON:RLM) and Nuformix (LON:NFX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Realm Therapeutics' return on equity of 0.00% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
Realm TherapeuticsN/A N/A N/A
Nuformix N/A -83.53%-17.20%

In the previous week, Realm Therapeutics' average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.

Company Overall Sentiment
Realm Therapeutics Neutral
Nuformix Neutral

Realm Therapeutics has higher revenue and earnings than Nuformix. Nuformix is trading at a lower price-to-earnings ratio than Realm Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Realm Therapeutics£501.92K0.00N/A-£17.50N/A
NuformixN/AN/A-£383.40K-£0.03N/A

0.1% of Nuformix shares are owned by institutional investors. 7.5% of Nuformix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Realm Therapeutics beats Nuformix on 4 of the 7 factors compared between the two stocks.

How does Nuformix compare to NetScientific?

NetScientific (LON:NSCI) and Nuformix (LON:NFX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

In the previous week, NetScientific had 1 more articles in the media than Nuformix. MarketBeat recorded 1 mentions for NetScientific and 0 mentions for Nuformix. NetScientific's average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.

Company Overall Sentiment
NetScientific Neutral
Nuformix Neutral

14.7% of NetScientific shares are held by institutional investors. Comparatively, 0.1% of Nuformix shares are held by institutional investors. 42.4% of NetScientific shares are held by company insiders. Comparatively, 7.5% of Nuformix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Nuformix has lower revenue, but higher earnings than NetScientific. Nuformix is trading at a lower price-to-earnings ratio than NetScientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NetScientific£1.45M0.00-£2.64M-£0.11N/A
NuformixN/AN/A-£383.40K-£0.03N/A

Nuformix has a net margin of 0.00% compared to NetScientific's net margin of -182.91%. NetScientific's return on equity of -13.70% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
NetScientific-182.91% -13.70% -9.42%
Nuformix N/A -83.53%-17.20%

NetScientific has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market. Comparatively, Nuformix has a beta of 1.537, meaning that its stock price is 54% more volatile than the broader market.

Summary

NetScientific beats Nuformix on 7 of the 11 factors compared between the two stocks.

How does Nuformix compare to Genflow Biosciences?

Genflow Biosciences (LON:GENF) and Nuformix (LON:NFX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Genflow Biosciences has a beta of 2.306, suggesting that its stock price is 131% more volatile than the broader market. Comparatively, Nuformix has a beta of 1.537, suggesting that its stock price is 54% more volatile than the broader market.

0.1% of Genflow Biosciences shares are held by institutional investors. Comparatively, 0.1% of Nuformix shares are held by institutional investors. 25.8% of Genflow Biosciences shares are held by insiders. Comparatively, 7.5% of Nuformix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Genflow Biosciences had 2 more articles in the media than Nuformix. MarketBeat recorded 2 mentions for Genflow Biosciences and 0 mentions for Nuformix. Genflow Biosciences' average media sentiment score of 0.16 beat Nuformix's score of 0.00 indicating that Genflow Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Genflow Biosciences Neutral
Nuformix Neutral

Genflow Biosciences has a net margin of 840.76% compared to Nuformix's net margin of 0.00%. Genflow Biosciences' return on equity of 377.33% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences840.76% 377.33% -58.66%
Nuformix N/A -83.53%-17.20%

Genflow Biosciences is trading at a lower price-to-earnings ratio than Nuformix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
NuformixN/AN/A-£383.40K-£0.03N/A

Summary

Genflow Biosciences beats Nuformix on 6 of the 11 factors compared between the two stocks.

How does Nuformix compare to Cizzle Biotechnology?

Cizzle Biotechnology (LON:CIZ) and Nuformix (LON:NFX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, Cizzle Biotechnology's average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.

Company Overall Sentiment
Cizzle Biotechnology Neutral
Nuformix Neutral

0.0% of Cizzle Biotechnology shares are owned by institutional investors. Comparatively, 0.1% of Nuformix shares are owned by institutional investors. 65.9% of Cizzle Biotechnology shares are owned by company insiders. Comparatively, 7.5% of Nuformix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cizzle Biotechnology has a beta of 0.022, suggesting that its stock price is 98% less volatile than the broader market. Comparatively, Nuformix has a beta of 1.537, suggesting that its stock price is 54% more volatile than the broader market.

Cizzle Biotechnology's return on equity of 104.99% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
Cizzle BiotechnologyN/A 104.99% -31.72%
Nuformix N/A -83.53%-17.20%

Cizzle Biotechnology is trading at a lower price-to-earnings ratio than Nuformix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cizzle BiotechnologyN/AN/A-£2.81K-£0.17N/A
NuformixN/AN/A-£383.40K-£0.03N/A

Summary

Nuformix beats Cizzle Biotechnology on 5 of the 8 factors compared between the two stocks.

Get Nuformix News Delivered to You Automatically

Sign up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NFX vs. The Competition

Export
MetricNuformixBiotechnology IndustryMedical SectorLON Exchange
Market Cap£5.17M£508.45M£6.85B£2.78B
Dividend YieldN/A3.87%2.66%6.14%
P/E Ratio-6.763.1126.04366.54
Price / SalesN/A6,785.72551.9585,951.69
Price / Cash3.5513.1329.0927.87
Price / Book0.3789.3710.987.75
Net Income-£383.40K-£96.07M£3.57B£5.89B
7 Day Performance4.21%1.23%3.06%-1.01%
1 Month Performance-4.81%-0.19%0.72%-1.74%
1 Year PerformanceN/A74.49%36.82%65.54%

Nuformix Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NFX
Nuformix
N/AGBX 0.20
+4.2%		N/A+90.0%£5.17MN/AN/A3
FAB
Fusion Antibodies
N/AGBX 13
+4.0%		N/A+75.3%£16.25M£1.60MN/A48
RLM
Realm Therapeutics
N/AN/AN/AN/A£13.41M£501.92KN/AN/A
NSCI
NetScientific
N/AN/AN/AN/A£12.81M£1.45MN/A26
GENF
Genflow Biosciences
N/AGBX 2.14
+1.9%		N/A+209.0%£12.12MN/AN/A5

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:NFX) was last updated on 6/29/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SpaceX is offering you shares. Don't take them.
SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...
Behind the Markets | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel